TYSABRI® (natalizumab) Information Center

by

2005 TYSABRI® News Archive

Biogen Idec and Elan Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for TYSABRI® in Multiple Sclerosis (11/17/05)

Elan and Biogen Idec Announce TYSABRI® Safety Evaluation Findings in Crohn’s Disease and Rheumatoid Arthritis Patients (10/17/05)

Biogen Idec and Elan Submit Supplemental Biologics License Application to the FDA for TYSABRI® in Multiple Sclerosis (9/26/05)

Elan and Biogen Idec Provide an Update on TYSABRI® (9/20/05)

Biogen Idec and Elan Announce TYSABRI® Safety Evaluation Update (8/9/05)

Two-Year Sentinel Data Evaluating TYSABRI® In Addition To AVONEX® Reinforce Efficacy In Multiple Sclerosis (7/18/05)

TYSABRI® Phase III Induction Trial In Crohn’s Disease Meets Primary Endpoint (6/30/05)

Letter in the New England Journal of Medicine (6/9/2005)

Positive One-Year Data From Sentinel Trial Evaluating Addition of TYSABRI® to AVONEX® Presented at American Academy of Neurology Meeting (4/13/05)

TYSABRI® Two-Year Monotherapy Data Support Positive One-Year Efficacy Findings and Show Significant Reduction in Risk of Disability Progression (4/12/05)

Elan and Biogen Idec Announce Update on TYSABRI (3/30/05)

Biogen Idec and Elan Announce Update on TYSABRI (3/3/05)

Webcast on Voluntary Suspension of TYSABRI (2/28/05)

Biogen Idec and Elan Announce Voluntary Suspension of TYSABRI (2/28/05)

 

Recent News